Heritable cancer predisposition testing in pediatric cancer patients excluding retinoblastoma in a middle‐income country
- 12 September 2022
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (11) , e29982
Abstract
Resource‐limited settings often have financial barriers to genetic testing for heritable cancer. This retrospective study investigated the pattern of heritable cancer predisposition testing in a middle‐income country over the period 2014–2021, excluding retinoblastoma. After establishing a specific fund in 2019, rate of tests increased from 1.1% to 10.9% of new diagnoses. Most common testing was for constitutional mismatch repair deficiency (CMMRD), rhabdoid predisposition syndrome, TP53 (tumor protein 53) mutation, and hereditary cancer panel. Of 33 patients, 13 (39%) tested positive, 12 (36%) negative, and eight (24%) had variants of unknown significance. Positivity rate was 43% for a clinical phenotype and 44% for a tumor type indication.Keywords
This publication has 26 references indexed in Scilit:
- Cancer Screening Recommendations for Individuals with Li-Fraumeni SyndromeClinical Cancer Research, 2017
- Childhood cancer predisposition syndromes—A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and HematologyAmerican Journal of Medical Genetics Part A, 2017
- Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational studyThe Lancet Oncology, 2016
- Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li‐Fraumeni syndrome cohortCancer, 2016
- Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid TumorsJAMA Oncology, 2016
- Germline Mutations in Predisposition Genes in Pediatric CancerNew England Journal of Medicine, 2016
- Recognition of genetic predisposition in pediatric cancer patients: An easy-to-use selection toolEuropean Journal of Medical Genetics, 2016
- Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in YouthJAMA, 2015
- Management of familial cancer: sequencing, surveillance and societyNature Reviews Clinical Oncology, 2014
- Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: Report from the constitutional mismatch repair deficiency consortiumEuropean Journal of Cancer, 2014